Optimizing Medtech Pricing Flexibility in a Digital World: Subscription Versus CapEx

As medtech companies modify their business practices and pricing models to draw out the maximum value of their integrated digital and medical device offerings and respond to customers’ concerns about high up-front costs of adopting new technologies, they need to discern the trade-offs and proper use cases.

View Resource

Orthopedic Industry Exhibits Steady Transactional Activity and Value, Despite Maturity

Outcome Capital argues that the orthopedic segment, and ortho in particular, remains highly attractive, as it offers investors stability, healthy multiples, and opportunities for innovation.

View Resource

Dx IPO Window Widens in 2021 as COVID-19 Testing Provides Jumping Off Point

Sustained investor interest in the diagnostics industry in light of the continuing COVID-19 pandemic drove initial public offerings in the Dx space in 2021, leading to more than three times as many IPOs in the space last year as in 2020.

View Resource

Diagnostics M&A Deals Skyrocket in 2021 as Companies Have COVID-19 Cash to Burn

As many diagnostics companies continued to benefit from high volumes of COVID-19testing, cash burned a hole in the pockets of many in the industry, and major players and smaller newbies alike picked up new businesses. 

View Resource

Diagnostic Financings Are Robust, Fueled by COVID-19 and Precision Medicine

Private investors poured more than $8 billion into diagnostics companies between January 2020 and September 30, 2021, envisioning myriad opportunities for innovative COVID-19 testing technologies and precision medicine tests that help optimize individual treatment regimens.

View Resource

Make, Buy Or Partner: Strategic Alliances Continue To Fuel Biopharma Growth

The biopharma market has been highly active throughout the COVID-19 pandemic with a substantial focus on strategic alliances between 2020-H1 2021. Partnership deals present exciting liquidity and risk mitigation opportunities for early-stage companies. Small molecules still comprise the largest segment of partnered drugs, but alliances for other modalities are on the rise.

View Resource

Pharma Services Sector Poised for Continued Growth and Consolidation

Outcome Capital has been following the pharma services market dynamics for the past 5 years. The authors believe that this fragmented segment will give way to greater consolidation by both financial buyers looking to roll up smaller players and larger contract research organizations seeking to expand into value-added specialty service areas. Adding to this consolidation is a tepid fund-raising environment, opening the door for financial buyers to play a role in consolidating many niche players.

View Resource

The Diagnostics Industry Post-Covid: A Revival or Return to Baseline?

The COVID-19 crisis shifted unprecedented resources to the diagnostics industry and presented a substantial growth opportunity for test manufacturers. A multitude of companies and entrepreneurs quickly pivoted toward developing innovative COVID tests, but whether they can survive post-pandemic exceptionalism remains to be seen.

View Resource

Intense Transactional Activity Continues To Propel Biopharma Growth

Due to the risks, costs, and required specialization associated with research and development, acquisitions and partnerships have become powerful and frequently used tools for large pharmaceutical companies to ensure continued growth. Outcome Capital’s analysis of M&A by the largest pharmaceutical companies over the past three-and-a-half-years reveals some important trends.

View Resource

7 Elements of a Successful Biotech Funding Plan

CEOs must accept the reality that the success of their company is largely dependent on segment dynamics, in addition to the technology or their management skills

View Resource

Immuno-Oncology: Unicorns, China And The Perfect Storm

Are we in the midst of a transformational inflection point in scientific progress leading to meaningful improvements in clinical outcomes or are we witnessing irrational exuberance by investors and strategic players leading to unduly escalated asset values? Time will tell.

View Resource

Strategy First, Execution Second: Why Life Science Entrepreneurs Should Adopt a Top-Down Mindset Early

Management teams should adopt a top-down approach by developing a clear path to liquidity aligned with sector-specific market characteristics

View Resource

Neurovascular Device Market Poised For Growth

Not long ago, tPA was the only front-line treatment for acute ischemic stroke. But a second generation of mechanical thrombectomy devices, including stent retrievers and aspiration-based reperfusion devices, has demonstrated significant efficacy against ischemic stroke, providing the impetus for renewed device innovation and new care delivery strategies.

View Resource

Recurring Mistakes (And Remedies) For Life Sciences M&A

Life science management teams fall victim to recurring mistakes and entrapments.  This article discusses avoidable missteps in M&A transactions and their respective remedies.

View Resource

Attracting Venture Capital in the Life Sciences Industry: a Data-driven Approach

Seeking venture capital (VC) financing for a young life sciences company is often a difficult and frustrating job, sometimes taking many months and too often ending fruitlessly.

View Resource

How Cognitive Bias Undermines Value Creation in Life Sciences M&A

Life Sciences mergers and acquisitions are typically based on perceived future value rather than objective financial parameters.

View Resource

Who’s Driving the Liquidity Event?

In a hard-hitting expert view piece, Dr Oded Ben-Joseph and Dr Shawn Manning, from investment bank Outcome Capital, advise on how life science companies can achieve shareholder objectives without falling into some common traps.

View Resource

Platforms versus Products in the Life Sciences Sector

In an expert view piece, Dr Oded Ben-Joseph and Dr Shawn Manning, from investment bank Outcome Capital, advise on how life sciences companies can curtail risk by allocating time and money in a capital-efficient manner.

View Resource

Business Success in the Life Sciences: an Investment Banker’s Perspective

We spent considerable time talking with biotech and pharma companies as well as academic research labs throughout the UK. Our aim was to get a more in-depth understanding of the local industry, its strengths, weaknesses and particular needs…

View Resource

Where the Bodies Lie

As members of a life sciences advisory and investment banking group, my partners and I have often noted that life sciences companies fall victim to the same mistakes and misconceptions, repeated again and again. These failures mostly hinge upon company management misunderstanding the fundamentals of market dynamics and failing to appreciate the importance of the exit…

View Resource

Contact Us for More Information

Would you like to learn more about working with Outcome Capital or discuss your specific needs?

Contact Us

  • Boston

    99 High St. Suite 2900, Boston, MA 02110
    (617) 431-2278